MBOT — Microbot Medical Inc.

Is MBOT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Strong Oversold As of November 17, 2026

Microbot Medical Inc. (MBOT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $0.64. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Microbot Medical Inc. (MBOT) appears to be a highly speculative, low‑liquidity microcap with limited public financial detail in the provided data. Absent confirmed revenue streams or recent filings, the primary value drivers are development progress and financing events, which expose the equity to dilution and binary regulatory/capability outcomes. Current market flows favor larger, defensive healthcare and pharma names rather than speculative device/development stories, increasing the likelihood of near‑term downside if financing or clinical signals disappoint.

Key factors

  • Limited public financial disclosure and no recent EDGAR filing analysis available, creating uncertainty on cash runway and revenue generation
  • Microcap equity with low liquidity, leading to higher volatility and wide bid/ask spreads
  • High dilution risk typical for small biotech/device issuers (convertible financings and equity raises common)
  • No clear commercialized, revenue-generating product disclosed in the provided data; development and regulatory execution required to create value
  • Sector dynamics favor large-cap pharma and certain device approvals (e.g., tubeless insulin pumps) which can shift investor flows away from speculative small-cap names
  • Macro sentiment is modestly risk-on, but current flows favor larger, defensive healthcare names rather than microcap developmental companies

Risks

  • Severe dilution from equity or convertible debt financing if cash runway is short
  • Regulatory setbacks or clinical failures that could halt development timelines
  • Competitive pressures from larger device and medtech companies (accelerated approvals in related device categories)
  • Extremely thin trading volume leading to price instability and difficulty executing larger orders
  • Lack of analyst coverage and limited institutional interest, reducing visibility and capital access
  • Adverse market moves (risk-off) would disproportionately hurt speculative microcaps like Microbot Medical Inc. (MBOT)

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MBOT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.